JPMorgan placed Revolution Medicines (RVMD) on the firm’s “Positive Catalyst Watch” List ahead of the RASolute 302 second-line pancreatic ductal adenocarcinoma readout in the first half of 2026. The firm has “high conviction” heading into the readout based on daraxonrasib’s performance compared to the chemo benchmark. It sees median overall survival of 9-10 months with a hazard ratio ranging from mid-0.6 to low-0.7 as a win scenario. JPMorgan keeps an Overweight rating on Revolution Medicines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines put volume heavy and directionally bearish
- Revolution Medicines price target raised to $122 from $92 at JPMorgan
- Revolution Medicines doses first patient in trial evaluating RMC-5127
- Revolution Medicines price target raised to $150 from $75 at Oppenheimer
- Revolution Medicines: Differentiated RAS(ON) Pipeline Underpins Overweight/Buy Rating and $92 December 2026 Target